Climate Change Data

Foresee Pharmaceuticals Co., Ltd.

Climate Impact & Sustainability Data (2023)

Reporting Period: 2023

Environmental Metrics

Total Carbon Emissions:231.817 tCO2e/year
Scope 1 Emissions:1.886 tCO2e/year
Scope 2 Emissions:229.931 tCO2e/year
Waste Generated:1.92 tons/year (liquid); 0.43 tons/year (solid)
Carbon Intensity:1.189 tCO2e/million NTD in 2023

ESG Focus Areas

  • Corporate Governance
  • Environmental Sustainability
  • Social Responsibility

Environmental Achievements

  • Implemented energy-efficient LED lighting and improved air conditioning to reduce electricity consumption.
  • Reduced per capita emissions by 10% by 2028 compared to 2023.

Social Achievements

  • Launched a “Turkey Earthquake Fundraiser” raising approximately NT$370,000.
  • Donated approximately NT$76,000 to seven charitable organizations.
  • Hosted a Thanksgiving event for patients and families from a rare disease foundation.

Governance Achievements

  • Established a Sustainable Development Group to drive sustainability initiatives.
  • Ranked in the top 21-35% of listed companies based on the TWSE Corporate Governance Evaluation System.

Climate Goals & Targets

Long-term Goals:
  • Not disclosed
Medium-term Goals:
  • Implement the “Waste Management Procedure Manual”.
  • Use ISO 14001 standards as environmental assessment criteria.
Short-term Goals:
  • Reduce per capita emissions by 10% by 2028.
  • Complete greenhouse gas inventory and verification by 2028.
  • Complete evaluation of suppliers on sustainability aspects by 2026.

Environmental Challenges

  • Challenges in patient recruitment for the Phase II clinical trial of FP-045 due to the rarity of Fanconi anemia.
  • Rising raw material costs.
  • Increased severity of extreme weather events.
Mitigation Strategies
  • US FDA agreed to relax inclusion criteria for FP-045 clinical trial.
  • Regular communication with suppliers to monitor material supply and production schedules.
  • Established a product safety stock and expanded global drug registrations.
  • Installed UPS systems to reduce operational disruptions from power outages.

Supply Chain Management

Supplier Audits: 5 on-site inspections of active pharmaceutical ingredient vendors and CDMO manufacturers in 2023; 100% overall supplier audit rate.

Responsible Procurement
  • Annual Vendor Evaluation assessing delivery timeliness, quality, price competitiveness, cooperation, and technical support.

Climate-Related Risks & Opportunities

Physical Risks
  • Increased severity of extreme weather events
  • Increased likelihood of extreme weather events
  • Increase in average temperature
Transition Risks
  • Carbon fees and carbon taxes
  • Introduction of new regulations
  • Rising raw material costs
  • Changes in customer behavior
  • Market risks
  • Increased negative feedback from stakeholders
Opportunities
  • Adopt more efficient transportation methods
  • Utilize more efficient production and distribution processes
  • Implement new technologies

Reporting Standards

Frameworks Used: GRI Standards 2021, TCFD, SASB

Third-party Assurance: Great International Certification Co., Ltd.

Sustainable Products & Innovation

  • CAMCEVI 42 mg (reduced patient visits and transportation emissions)

Awards & Recognition

  • 2022 Taipei Biotech Awards – Go Global Award (Gold Medal)
  • 2022 National Innovation Awards – Sustainable Model Award